MarginsXMarginsX
Home › Markets › Health Care › MTRI

Mentari Therapeutics Inc. (MTRI)

MTRI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$19.87
+6.83% on the day
Market cap
$1.0B
Small cap
Revenue · 2025
$4.9M
+7.5% on 2024
Net income · 2025
-$8.2M
-165.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-06-30, https://www.sec.gov/Archives/edgar/data/1728328/000121390025090210/0001213900-25-090210-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-06-30.

Profile

FieldValue
TickerMTRI on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryCanada
IPO yearNot reported by the screener
SEC CIK0001728328
SEC industry codePharmaceutical Preparations
Incorporated inBC

Financials · 2025

LineValue
Revenue$4.9M
Net income-$8.2M
Operating incomeNot in SEC XBRL data
Net margin-165.1%
Operating marginOperating income not reported
Revenue growth+7.5%
Cash$11.1M
Total assets$15.6M
P/E (computed)Net income was not positive
P/S (computed)212.3×

Warning signs

Cash runway
1.7 months
$1.1M cash at September 30, 2026
Share count, 1 year
+95.9%
2025-10-31 to 2026-10-30 · +1990.9% over 3 years
Going-concern doubt
Yes
10-Q filed November 3, 2026
Insider net buying, 12 months
$1.3M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"The Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued."
10-Q 2026-11-03
Cash and burn$1.1M cash; operating cash flow -$2.0M a quarter.Report 2026-09-30
Shares outstandingNo cover-page share count in XBRLCover page 2026-10-30
Reverse splits, 3 years2; latest 1-for-10 on 2026-11-05Source 2026-11-05
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-04-03
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-09-18
AuditorCBIZ CPAs P.C., New York, New York, United States; changed auditors 1 time in 24 months8-K 4.01 2025-06-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $1.3M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q1 2027
2026-09-30
Not filed-$2.3M-$1.1M$1.1MNo debt tagsNeeds four quarters10-Q 2026-11-03
Q4 2026
2026-06-30
Not filed-$5.8M-$3.0M$2.2MNo debt tagsNeeds four quarters10-K 2026-09-09
Q3 2026
2026-03-31
Not filed-$3.0M-$1.7M$5.2MNo debt tagsNeeds four quarters10-Q 2026-05-06
Q2 2026
2025-12-31
$820K-$2.0M-$2.1M$7.0MNo debt tags$4.5M10-Q 2026-02-11
Q1 2026
2025-09-30
$1.1M-$1.7M-$1.9M$9.3MNo debt tags$4.8M10-Q 2025-11-06
Q4 2025
2025-06-30
$1.3M$4.7M-$2.1M$10.7MNo debt tags$4.9M10-K 2025-09-23
Q3 2025
2025-03-31
$1.3M-$2.1M-$1.7M$4.7MNo debt tags$4.9M10-Q 2025-05-12
Q2 2025
2024-12-31
$1.1M-$2.6M-$2.5M$3.4MNo debt tags$4.8M10-Q 2026-02-11

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-10-28
Latest annual report
ANNUAL REPORT
10-K2026-09-09
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-11-03
Latest current report8-K2026-11-16
Latest proxy
DEFINITIVE ADDITIONAL MATERIALS
DEFA14A2025-11-03

Source: SEC EDGAR submissions feed, 537 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+19.5%
1 month+39.8%
3 months+30.1%
Year to date+75.5%
1 year+2.8%
From 52-week high0.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
SPTXSeaport Therapeutics Inc.$19.12-4.30%$1.0B
ANROAlto Neuroscience Inc.$27.12-8.19%$1.1B
HROWHarrow Inc.$29.09-3.42%$1.1B
CYRXCryoPort Inc.$19.80-0.45%$1.0B
MLTXMoonLake Immunotherapeutics$11.73-6.16%$998.3M
SVRASavara Inc.$4.46-3.77%$985.1M
JBIOJade Biosciences Inc.$15.34-4.99%$975.3M
VSTMVerastem Inc.$7.70-5.87%$970.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier